Cite
HARVARD Citation
Witzens-Harig, M. et al. (2021). The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial. HemaSphere. 5 (10), pp. e636-. [Online].